NO20003960L - Salter av paroxsetine - Google Patents

Salter av paroxsetine

Info

Publication number
NO20003960L
NO20003960L NO20003960A NO20003960A NO20003960L NO 20003960 L NO20003960 L NO 20003960L NO 20003960 A NO20003960 A NO 20003960A NO 20003960 A NO20003960 A NO 20003960A NO 20003960 L NO20003960 L NO 20003960L
Authority
NO
Norway
Prior art keywords
paroxsetine
salts
hypophosphoric
methylbenzenesulfonic
paroxetine
Prior art date
Application number
NO20003960A
Other languages
English (en)
Other versions
NO20003960D0 (no
Inventor
David Crowe
Deirdre O'keeffe
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802656.0A external-priority patent/GB9802656D0/en
Priority claimed from GBGB9802698.2A external-priority patent/GB9802698D0/en
Priority claimed from GBGB9802654.5A external-priority patent/GB9802654D0/en
Priority claimed from GBGB9802661.0A external-priority patent/GB9802661D0/en
Priority claimed from GBGB9802644.6A external-priority patent/GB9802644D0/en
Priority claimed from GBGB9802638.8A external-priority patent/GB9802638D0/en
Priority claimed from GBGB9802645.3A external-priority patent/GB9802645D0/en
Priority claimed from GBGB9802653.7A external-priority patent/GB9802653D0/en
Priority claimed from GBGB9802646.1A external-priority patent/GB9802646D0/en
Priority claimed from GBGB9802657.8A external-priority patent/GB9802657D0/en
Priority claimed from GBGB9802639.6A external-priority patent/GB9802639D0/en
Priority claimed from GBGB9802659.4A external-priority patent/GB9802659D0/en
Priority claimed from GBGB9802655.2A external-priority patent/GB9802655D0/en
Priority claimed from GBGB9802640.4A external-priority patent/GB9802640D0/en
Priority claimed from GBGB9802665.1A external-priority patent/GB9802665D0/en
Priority claimed from GBGB9802664.4A external-priority patent/GB9802664D0/en
Priority claimed from GBGB9802658.6A external-priority patent/GB9802658D0/en
Priority claimed from GBGB9817309.9A external-priority patent/GB9817309D0/en
Priority claimed from GBGB9817307.3A external-priority patent/GB9817307D0/en
Priority claimed from GBGB9817364.4A external-priority patent/GB9817364D0/en
Priority claimed from GBGB9817359.4A external-priority patent/GB9817359D0/en
Priority claimed from GBGB9817317.2A external-priority patent/GB9817317D0/en
Priority claimed from GBGB9817360.2A external-priority patent/GB9817360D0/en
Priority claimed from GBGB9817340.4A external-priority patent/GB9817340D0/en
Priority claimed from GBGB9817321.4A external-priority patent/GB9817321D0/en
Priority claimed from GBGB9817344.6A external-priority patent/GB9817344D0/en
Priority claimed from GBGB9817322.2A external-priority patent/GB9817322D0/en
Priority claimed from GBGB9817320.6A external-priority patent/GB9817320D0/en
Priority claimed from GBGB9826173.8A external-priority patent/GB9826173D0/en
Priority claimed from GBGB9826172.0A external-priority patent/GB9826172D0/en
Priority claimed from GBGB9827341.0A external-priority patent/GB9827341D0/en
Priority claimed from GBGB9827277.6A external-priority patent/GB9827277D0/en
Priority claimed from GBGB9828775.8A external-priority patent/GB9828775D0/en
Publication of NO20003960D0 publication Critical patent/NO20003960D0/no
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20003960L publication Critical patent/NO20003960L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Salt av paroxetine med en syre valgt fra gruppen bestående av svovelsyre, vinsyre, oksalsyre, fumarsyre, propionsyre, maursyre, glutaminsyre, ravsyre, benzosyre, sitronsyre, salpetersyre, fosforsyre, 4-metylbenzensulfonsyre, hypofosforsyrling, melkesyre og mandelsyrer og glycin er nyttige ved behandling og forebygging av visse CNS-lidelser.
NO20003960A 1998-02-06 2000-08-04 Salter av paroxsetine NO20003960L (no)

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
GBGB9802661.0A GB9802661D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802644.6A GB9802644D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802638.8A GB9802638D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802645.3A GB9802645D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802653.7A GB9802653D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802646.1A GB9802646D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802657.8A GB9802657D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802639.6A GB9802639D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802659.4A GB9802659D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802655.2A GB9802655D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802640.4A GB9802640D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802665.1A GB9802665D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802664.4A GB9802664D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802654.5A GB9802654D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802658.6A GB9802658D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802656.0A GB9802656D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802698.2A GB9802698D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9817359.4A GB9817359D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817317.2A GB9817317D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817360.2A GB9817360D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817340.4A GB9817340D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817321.4A GB9817321D0 (en) 1998-08-08 1998-08-08 Novel compound
GBGB9817309.9A GB9817309D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817307.3A GB9817307D0 (en) 1998-08-08 1998-08-08 Novel compound
GBGB9817364.4A GB9817364D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817344.6A GB9817344D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817322.2A GB9817322D0 (en) 1998-08-10 1998-08-10 Novel compounds
GBGB9817320.6A GB9817320D0 (en) 1998-08-10 1998-08-10 Novel compounds
GBGB9826173.8A GB9826173D0 (en) 1998-11-30 1998-11-30 Novel compounds
GBGB9826172.0A GB9826172D0 (en) 1998-11-30 1998-11-30 Novel compound
GBGB9827341.0A GB9827341D0 (en) 1998-12-11 1998-12-11 Novel compounds
GBGB9827277.6A GB9827277D0 (en) 1998-12-11 1998-12-11 Novel compound
GBGB9828775.8A GB9828775D0 (en) 1998-12-29 1998-12-29 Novel compounds
PCT/GB1999/000380 WO1999040084A1 (en) 1998-02-06 1999-02-05 Salts of paroxetine

Publications (2)

Publication Number Publication Date
NO20003960D0 NO20003960D0 (no) 2000-08-04
NO20003960L true NO20003960L (no) 2000-09-25

Family

ID=27586915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003960A NO20003960L (no) 1998-02-06 2000-08-04 Salter av paroxsetine

Country Status (11)

Country Link
EP (1) EP1053234A1 (no)
JP (1) JP2002505254A (no)
KR (1) KR20010040711A (no)
BG (1) BG104737A (no)
CA (1) CA2319652A1 (no)
EA (1) EA200000815A1 (no)
IL (1) IL137684A0 (no)
NO (1) NO20003960L (no)
PL (1) PL342295A1 (no)
SK (1) SK11812000A3 (no)
WO (1) WO1999040084A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
EP1102764A1 (en) * 1998-08-08 2001-05-30 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
CZ20031856A3 (cs) * 2001-01-05 2003-09-17 Eli Lilly And Company Antagonisté receptorů excitačních aminokyselin
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CN108218844B (zh) * 2018-03-08 2021-01-19 合肥科大生物技术有限公司 一种美金刚帕罗西汀共晶盐及其制备方法、药物组合物、应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására

Also Published As

Publication number Publication date
SK11812000A3 (sk) 2001-08-06
CA2319652A1 (en) 1999-08-12
BG104737A (en) 2001-07-31
KR20010040711A (ko) 2001-05-15
NO20003960D0 (no) 2000-08-04
PL342295A1 (en) 2001-06-04
EA200000815A1 (ru) 2001-02-26
EP1053234A1 (en) 2000-11-22
IL137684A0 (en) 2001-10-31
WO1999040084A1 (en) 1999-08-12
JP2002505254A (ja) 2002-02-19

Similar Documents

Publication Publication Date Title
MXPA03006248A (es) Derivados de acido fumarico como inhibidores de nf-kappab.
DK0574313T3 (da) 1,4-disubstituerede piperaziner til behandling af sygdomme i centralnervesystemet og neuroendocrine sygdomme
CA2388142A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
YU48002A (sh) Derivati pirolidina kao inhibitori ciklične amp-specifične fosfodiesteraze
HUP0003863A3 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
WO2002044142A3 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
DK1236728T3 (da) S-type 2-substituerede hydroxy-2-indolidinylsmörsyreesterforbindelser og fremgangsmåde til fremstilling deraf
NO20000093D0 (no) (+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser
NO20016201L (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
MX224669B (es) Procedimiento para la preparacion de sales de acido carboxilico a partir de alcoholes primarios.
EA200000815A1 (ru) Соли пароксетина
MXPA03007455A (es) Metodo y produccion de acido d-pantotenico y las sales de este como adyuvante en productos alimenticios para animales.
NO912475D0 (no) Tiazolidinkarboksylsyreamidderivater med antiallergisk aktivitet, og fremgangsmaate til fremstilling derav.
JO2181B1 (en) Procalopride solution is taken by mouth
ATE257818T1 (de) Verfahren zur herstellung von wasserfreier gabapentin von pharmazeutischer qualität
MY126789A (en) Intermediates for the production of quinoline carboxylic acid derivatives
SG77692A1 (en) Process and intermediates for the manufacture of pyridine-2, 3-dicarboxylate compounds
MXPA03008119A (es) Metodo para la produccion de 2,6-dialquilmorfolinas n-sustituidas.
WO2002066665A3 (de) Verfahren zur herstellung von d-pantothensäure und/oder deren salze als zusatz zu tierfuttermitteln
MXPA03009681A (es) METODO PARA TRATAMIENTO DE TUMORES POR ADMINISTRACIoN DE TEGAFUR, URACILO, ACIDO FOLINICO, Y CICLOFOSFAMIDA.
IL157496A0 (en) Method for producing d-pantothenic acid and/or salts thereof as additive to animal feed
NO20044629L (no) Fremgangsmate til fremstilling av sure salter av gemifloksasin.
AP2000001879A0 (en) Salts of paroxetine.
ATE163951T1 (de) Verfahren zur herstellung von polyasparaginsäure und/oder polyasparaginsäureimiden
DE59806820D1 (de) Hydroximsäurehalogenide, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application